Peri‑operative Hydrocortisone Management for Diabetic Patients with Adrenal Insufficiency Undergoing Endoscopic Procedures

Indications for Peri‑operative Hydrocortisone

• Hydrocortisone stress‑dose is recommended for patients with known primary or secondary adrenal insufficiency undergoing any surgical or endoscopic procedure. (Association of Anaesthetists guideline) 1
• Patients receiving chronic glucocorticoid therapy equivalent to ≥5 mg prednisolone daily for ≥4 weeks should receive peri‑operative hydrocortisone to cover potential HPA‑axis suppression. 2
• A history of glucocorticoid use within the past year that may have suppressed the HPA axis also warrants stress‑dose hydrocortisone. 3

Dosing Recommendations for Endoscopic Procedures (EGD / Colonoscopy)

• At the start of the endoscopic procedure, administer hydrocortisone 100 mg intravenously or intramuscularly to patients meeting the above indications. (Association of Anaesthetists) 1
• If the patient has confirmed adrenal insufficiency and recovers without complications, resume the usual oral glucocorticoid regimen once oral intake is possible. 1
• When there is uncertainty about HPA‑axis function, manage the patient as if they have primary adrenal insufficiency, continuing appropriate steroid coverage. 1
• For patients on chronic steroids without confirmed adrenal insufficiency, continue their regular glucocorticoid dose; if nil‑by‑mouth status is expected, use an equivalent intravenous dosing regimen. 1

Glucose Management in Diabetic Patients Receiving Hydrocortisone

• Implement more frequent peri‑operative glucose monitoring when glucocorticoids are administered. 4
• Recognize that stress‑dose hydrocortisone can cause afternoon and evening hyperglycaemia, necessitating tighter control. 4
• In insulin‑treated diabetic patients, consider adding intermediate‑acting insulin (e.g., NPH 0.1–0.3 U/kg/day) to the usual regimen during the period of glucocorticoid exposure. 4
• Expect transient hyperglycaemia after a 100 mg hydrocortisone dose and be prepared to use a more resistant sliding‑scale insulin protocol initially. 4
• Be aware that insulin requirements may fall rapidly as the glucocorticoid effect wanes, requiring prompt dose reduction. 4

Risks and Safety Considerations

• Steroid exposure increases the risk of colonoscopic perforation in patients with inflammatory bowel disease (adjusted OR ≈ 7.7), especially when combined with severe endoscopic disease. This risk reflects chronic steroid use and disease severity rather than a single peri‑operative dose. 3
• Withholding necessary stress‑dose steroids poses a greater danger; adrenal crisis mortality is 2–3 times higher in secondary adrenal insufficiency, and ≈ 8.6 % of crises are triggered by inadequate hospital dosing. 3

Practical Recommendations When Uncertainty Exists

• If the need for peri‑operative glucocorticoids is unclear, administer stress‑dose hydrocortisone; short‑term use has no documented long‑term adverse consequences. (Association of Anaesthetists) [2][3]
• During bowel‑preparation for colonoscopy, consider intravenous fluids and a prophylactic glucocorticoid dose for patients with significant adrenal insufficiency, and maintain vigilant glucose monitoring due to the combined effects of dehydration and steroid‑induced hyperglycaemia. [1][4]

Guidelines for Management of Glucocorticoid‑Induced Adrenal Insufficiency

1. Preferred Maintenance Replacement

• Hydrocortisone is the preferred glucocorticoid for chronic replacement because its pharmacokinetic profile more closely reproduces the normal circadian rhythm of endogenous cortisol. 5

2. Stress‑Dosing During Acute Illness

• In the setting of acute intercurrent illness (e.g., gastroenteritis, fever, infection), the daily glucocorticoid dose should be doubled until full clinical recovery is achieved. [6][7]8
• Approximately half of individuals with a prior adrenal crisis report that subsequent crises were precipitated by such intercurrent illnesses. 6

3. Peri‑operative Glucocorticoid Management

3.1 Major Surgery

• Induction: Administer 100 mg hydrocortisone intravenously at the start of anesthesia. 5
• Intra‑operative & early postoperative period: Follow with a continuous infusion of hydrocortisone 200 mg per 24 h (or an equivalent regimen such as 50 mg every 6 h intramuscularly). [5][9]10
• Alternative regimen: A single dose of dexamethasone 6–8 mg IV can provide adequate coverage for the first 24 h. 9
• Post‑operative oral transition: When the patient can tolerate oral intake and recovery is uncomplicated, double the usual oral glucocorticoid dose for 48 h before returning to the maintenance regimen. [9][6]
• Unstable postoperative course: If the patient remains clinically unstable, maintain double the usual dose for up to one week after surgery. [6][11]

3.2 Intermediate‑duration or Surface‑area Surgery

• Give 100 mg hydrocortisone IV at induction, then continue a 200 mg/24 h infusion. 9
• If recovery is uncomplicated, double the regular oral dose for 48 h after surgery. 9

3.3 Minor Procedures

• Pre‑procedure: Double the morning hydrocortisone dose immediately before the procedure. 8
• Post‑procedure: Resume the usual maintenance dose once the procedure is completed. 8

4. Incidence, Mortality, and Risk Factors for Adrenal Crisis

• The incidence of adrenal crisis in patients with secondary adrenal insufficiency is 6–8 events per 100 patient‑years. [6][7]
• Mortality among these patients is 2–3 times higher than in the general population. [6][7]
• Co‑existing conditions such as asthma or diabetes increase vulnerability to crisis. [6][12]
• 8.6 % of patients report a prior crisis that was triggered by inadequate glucocorticoid dosing during hospitalization. [6][11]

5. Glucocorticoid Tapering and Risk of Suppression

• A daily dose equivalent to prednisolone ≥ 5 mg for ≥ 4 weeks carries a significant risk of adrenal suppression. [13][7]14

6. Relative Adrenal Insufficiency During Physiologic Stress

• Clinical features of adrenal crisis (hypotension, altered mental status, hyponatremia) can occur even when plasma cortisol concentrations are normal or elevated, underscoring that cortisol levels alone should not guide stress‑dosing decisions. [6][11]

Management of Etomidate‑Induced Adrenal Suppression in Patients with Adrenal Insufficiency

Mechanism of Adrenal Suppression

• Etomidate rapidly suppresses cortisol production by inhibiting the enzyme 11‑β‑hydroxylase, which catalyzes the final step of cortisol biosynthesis【15】【16】.

Induction‑Phase Steroid Replacement

Recommended Hydrocortisone Regimen

• For any patient with known adrenal insufficiency (or suspected HPA‑axis suppression) who receives etomidate, give hydrocortisone 100 mg IV at induction and then start a continuous infusion of hydrocortisone 200 mg per 24 h; continue the infusion until the patient can tolerate oral glucocorticoids【15】【16】【17】.
• The continuous infusion is preferred over intermittent bolus dosing because it better maintains physiologic cortisol levels【15】【16】【18】.

Duration of Therapy

• In uncomplicated cases, maintain the infusion for at least 48 hours; extend up to one week for patients with a more complicated recovery【17】.

Monitoring for Adrenal Crisis

• Watch for early signs such as malaise, somnolence, orthostatic hypotension, and hyponatremia, and for late signs like volume‑resistant hypotension【15】【18】【19】.
• If an adrenal crisis is suspected, increase hydrocortisone dosing immediately【15】【16】.

Special Populations

Chronic Glucocorticoid Users

• Patients receiving ≥5 mg prednisolone daily for ≥4 weeks (potential HPA‑axis suppression) should be managed identically to those with confirmed adrenal insufficiency when etomidate is used【20】.

CYP3A4 Inducers and Obese Patients

• Higher hydrocortisone doses may be required in patients on CYP3A4‑inducing drugs or with obesity【15】【16】【18】.
• Initiating a continuous infusion in these groups helps reduce the risk of decompensation【15】【16】【18】.

Evidence Summary for Single‑Dose Etomidate

• Some in‑vivo studies found no clinically relevant cortisol changes after a single etomidate dose【15】【16】.
• Conversely, adverse outcomes have been documented with etomidate infusions【15】【16】.
• The guideline emphasizes that clinical judgement is required; when uncertainty exists about the need for glucocorticoids, they should be administered because short‑term use has no known long‑term adverse effects【15】【16】【20】【17】.

Pitfalls to Avoid

• Do not use dexamethasone alone for primary adrenal insufficiency because it lacks mineralocorticoid activity【16】【20】【17】.

Practical Implementation Summary

• Treat every patient with known or suspected adrenal insufficiency receiving etomidate as if complete adrenal suppression will occur【15】【16】.
• Apply the hydrocortisone dosing and infusion strategy outlined above, adjust duration based on clinical course, and monitor vigilantly for signs of crisis.